VIVXF (Avivagen) LT-Debt-to-Total-Asset: 4.03 (As of Jul. 2023)


What is Avivagen LT-Debt-to-Total-Asset?

Avivagen VIVXF -99.00% LT-Debt-to-Total-Asset is 4.03 as of Jul. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Avivagen's long-term debt to total assests ratio for the quarter that ended in Jul. 2023 was 4.03.

Avivagen's long-term debt to total assets ratio increased from Jul. 2022 (3.02) to Jul. 2023 (4.03). It may suggest that Avivagen is progressively becoming more dependent on debt to grow their business.

Avivagen  (OTCPK:VIVXF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Avivagen LT-Debt-to-Total-Asset Related Terms

Avivagen LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Avivagen's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen LT-Debt-to-Total-Asset Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 2.04 2.11 0.41 3.85

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.02 3.85 9.52 4.10 4.03

Avivagen LT-Debt-to-Total-Asset Calculation

Avivagen's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2022 is calculated as

LT Debt to Total Assets (A: Oct. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Oct. 2022 )/Total Assets (A: Oct. 2022 )
=3.836/0.997
=3.85

Avivagen's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jul. 2023 is calculated as

LT Debt to Total Assets (Q: Jul. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Jul. 2023 )/Total Assets (Q: Jul. 2023 )
=0.834/0.207
=4.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 4.03 mean?
Avivagen (VIVXF) has a LT-Debt-to-Total-Asset of 4.03 as of Jul. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Avivagen and its competitors.
Is Avivagen's LT-Debt-to-Total-Asset too high?
Avivagen's current LT-Debt-to-Total-Asset is 4.03.
How does Avivagen's LT-Debt-to-Total-Asset compare to DMKPQ and MJNE?
Avivagen's LT-Debt-to-Total-Asset of 4.03 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Avivagen and its competitors. Avivagen's current LT-Debt-to-Total-Asset is 4.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current LT-Debt-to-Total-Asset of 4.03. The current LT-Debt-to-Total-Asset is 4.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Avivagen (VIVXF), the current LT-Debt-to-Total-Asset is 4.03 as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.